Phase II Preclinical Drug Screening in Human Tumor Xenografts: A First European Multicenter Collaborative Study

Cancer Research

Volumn 52, Issue 21, 1992, Pages 5940-5947

  Patrick Dumont, M ^d,h   Fiebig, Heiner H ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Treatment of Cancer ^*  (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

^d JULES BORDET INSTITUTE   (Belgium)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f WESTERN GENERAL HOSPITAL   (United Kingdom)

^g BRISTOL MYERS SQUIBB   (United States)

^h CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BREQUINAR; DATELLIPTIUM CHLORIDE; DOXORUBICIN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TOLERANCE; FEMALE; GROWTH RATE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELIABILITY; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

AMSACRINE; ANIMAL; ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; BODY WEIGHT; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ELLIPTICINES; EUROPE; FEMALE; HUMAN; MICE; MICE, INBRED BALB C; MICE, NUDE; SUPPORT, NON-U.S. GOV'T; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0026452172     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Shoemaker, R. H., McLemore, T. L., Abbott, B. J., Fine, D. L., Gorelik, E., Mayo, J. G., Fodstad, O., and Boyd, M. R. Human tumour xenograft models for use with an in vitro-based disease-oriented antitumour drug screening program. In: B. Winograd, M. J. Peckham, and H. M. Pinedo (eds.). Human Tumour Xenografts in Anticancer Drug Development, pp. 115-120. Berlin and Heidelberg: Springer-Verlag, 1988.
2. Suquet, M. J., Byar, D. P., Green, S. B., and Rozencweig, M. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat. Rep., 67: 753-765, 1983.
3. Venditti, J. M. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary. Cancer Treat. Rep., 67: 767-772, 1983.
4. Atassi, G., and Staquet, M. The clinical predictive value of the mouse screening methods. In: P. Hilgard and K. Hellmann (eds.), Anticancer Drug Development, pp. 27-34. Barcelona: J. R. Prous Publishers, 1983.
5. Corbett, T. H., Valeriote, F. A., and Baker, L. H. Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs, 5: 3-20, 1987.
6. Marsoni, S., Hoth, D., Simon, R., Leyland-Jones, B., DeRosa, M., and Wittes, R. E. Clinical drug development: an analysis of phase II trials, 19701985. Cancer Treat. Rep., 71: 71-80, 1987.
7. Pinedo, H. M. Development of new anti-cancer drugs. Med. Oncol. Tumor Pharmacother., 3:63-69, 1986.
8. Boven, E., and Winograd, B. (eds.). The Nude Mouse in Oncology Research, pp. 1-340, Boca Raton, FL: CRC Press, 1991.
9. Houghton, J. A., and Taylor, D. M. Maintenance of biological and biochemical characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br. J. Cancer, 37: 199-212, 1978.
10. Fiebig, H. H., Widmer, K. H., Fiedler, L., Wittekind, O., and Lohr, G. W. Development and characterization of 51 human tumor models for large bowel, stomach and esophageal cancer. Dig. Surg., 1:225-235, 1984.
11. Molthoff, C. F. M., Calame, J. J., Pinedo, H. M., and Boven, E. Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int. J. Cancer, 47: 72-79, 1991.
12. Steel, G. G., Courtenay, V. D., and Peckham, M. J. The response to chemotherapy of a variety of human tumour xenografts. Br. J. Cancer, 47: 1-13, 1983.
13. Winograd, B., Boven, E., Lobbezoo, M. W., and Pinedo, H. M. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development. In Vivo, 1: 1-14, 1987.
14. Mattem, J., Bak, M., Hahn, E. W., and Volm, M. Human tumor xenografts as model for drug testing. Cancer Metastasis Rev., 7: 263-284, 1988.
15. Boven, E., Winograd, B., Fodstad, 0., Lobbezoo, M. W., and Pinedo, H. M. Preclinical phase II studies in human tumor lines: a European multicenter study. Eur. J. Cancer Clin. Oncol., 24: 567-573, 1988.
16. Young, R. C., Ozols, R. F., and Myers, C. E. The anthracycline antineoplastic drugs. N. Engl. J. Med., 305: 139-153, 1981.
17. Louie, A. C., and Issell, B. F. Amsacrine (AMSA)-a clinical review. J. Clin. Oncol., 3: 562-592, 1985.
18. Schwartsmann, G., Peters, G. J., Laurensse, E., De Waal, F. C., Loonen, A. H., Uyva, A., and Pinedo, H. M. DUP785 (NSC 368390): schedule-depen-dency of growth-inhibitory and antipyrimidine effects. Biochem. Pharmacol., 37: 3257-3266, 1988.
19. Shen, H. S. L., Chen, S. F., Behrens, D. L., Whitney, C. C., Dexter, D. L., and Forbes, M. Distribution of the novel anticancer drug candidate brequinar sodium (EhiP785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenografts. Cancer Chemother. Pharmacol., 22: 183-186,1988.
20. Arteaga, C. L., Brown, T. D., Kuhn, J. G., Shen, H. S. L., O'Rourke, T. J., Beougher, K., Brentzel, H. J., Von Hoff, D. D., and Weiss, G. R. Phase I clinical and pharmacokinetic trial of brequinar sodium (DUP785; NSC 368390). Cancer Res., 49:4648-4653, 1989.
21. Bork, E., Vest, S., and Hansen, H. H. A phase I clinical and pharmacokinetic study of brequinar sodium, DUP785 (NSC 368390), using a weekly and a biweekly schedule. Eur. J. Cancer Qin. Oncol., 25: 1403-1411, 1989.
22. Schwartsmann, G., Dodion, P., Vermorken, J. B., Ten Bokkel Huinink, W. W., Joggi, J., Winograd, B., Gall, H., Simonetti, G., Van der Vygh, W. J. F., Van Hennik, M. B., Crespeigne, N., and Pinedo, H. M. Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies. Cancer Chemother. Pharmacol., 25:345-351, 1990.
23. Peters, G. J., Schwartsmann, G., Nadal, J. C., Laurensse, E. J., Van Gröeningen, C. J., Van der Vagh, W. J. F., and Pinedo, H. M. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequi nar sodium (DUP-785; NSC 3683W) in mice and patients. Cancer Res., 50: 4644-4649, 1990.
24. Nsari, B. M., and Thompson, E. N. Methoxy-9-ellipticine lactate in refractory acute myeloid leukemia. Postgrad. Med. J., 51: 103-105, 1975.
25. Treat, J., Greenspan, A., Rahman, A., McCabe, M. S., and Byrne, P. J. Elliptinium: phase II study in advanced measurable breast cancer. Invest. New Drugs, 7: 231-234, 1989.
26. Buzdar, A. U., Hortobagyi, G. N., Esparza, L. T., Holmes, F. A., Ro, J. S., Fraschini, G., and Lichtiger, B. Elliptinium acetate in metasUtic breast cancer-a phase II study. Oncology (Basel), 47: 101-104, 1990.
27. Auclair, C., Pierre, A., Voisin, E., Pepin, O., Cros, S., Colas, C., Saucier, J-M., Verschuere, B., Gros, P., and Paoletti, C. Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylami-no-2-ethyl)-9-hydroxy ellipticinium chloride, HCl. Cancer Res., 47: 6254-6261, 1987.
28. Mucci-LoRusso, P., Polin, L., Biemat, L. A., Valeriote, F. A., and Corbett, T. H. Activity of datelliptium aceute (NSC 311152: SR 95156A) against solid tumors of mice. Invest. New Drugs, 8:253-261, 1990.
29. Turpin, F., Namer, M., Spielmann, M., Vuillemin, E., Mobayan, H., and Azab, M. Phase II trial of datelliptium chloride hydrochloride in metastatic breast cancer. Proc. Am. Assoc. Cancer Res., 33: 214, 1992.
30. Braakhuis, B. J. M., and Van Dongen, G. A. M. S. Limitations for treatment studies. In: E. Boven and B. Winograd (eds.). The Nude Mouse in Oncology Research, pp. 291-303. Boca Raton, FL: CRC Press, 1991.